RecruitingPhase 2NCT05526989
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Studying Squamous cell carcinoma of the penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Juskaran Chadha, DOMoffitt Cancer Center
- Intervention
- Dostarlimab(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2022 – 2027
Study locations (2)
- Moffitt Cancer Center, Tampa, Florida, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05526989 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the penis
Additional recruiting or active studies for the same condition.